ALNYLAM PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK: 0001178670
Period of Report: 2021-12-10

Reporting Person: MARAGANORE JOHN (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-10	Common Stock	M	1036	$96.45	Acquired	215801	Direct
2021-12-10	Common Stock	M	1124	$88.95	Acquired	216925	Direct
2021-12-10	Common Stock	M	839	$119.13	Acquired	217764	Direct
2021-12-10	Common Stock	M	2368	$42.22	Acquired	220132	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-10	Stock Option (right to buy)	$42.22	M	2368	Disposed	2026-12-20	Common Stock (2368)	Direct
2021-12-10	Stock Option (right to buy)	$88.95	M	1124	Disposed	2025-12-18	Common Stock (1124)	Direct
2021-12-10	Stock Option (right to buy)	$96.45	M	1036	Disposed	2024-12-17	Common Stock (1036)	Direct
2021-12-10	Stock Option (right to buy)	$119.13	M	839	Disposed	2028-02-28	Common Stock (839)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3133	Indirect

Footnotes

F1: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

F2: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

F3: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months.